17 citations
,
December 1997 in “Transplantation” Tacrolimus can cause hair loss in kidney transplant patients.
3 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Biological therapy boosts the immune system to effectively fight melanoma.
85 citations
,
January 1996 in “International Journal of Cancer” AS101 reduces hair loss from chemotherapy.
8 citations
,
September 2013 in “Molecular carcinogenesis” Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
2 citations
,
October 2022 in “Dermatologic Therapy” Baricitinib may effectively treat lichen planopilaris.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
4 citations
,
September 2020 in “Cell division” XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.
40 citations
,
August 2005 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Acitretin moderately improved skin and eye issues but not hair loss or light sensitivity in a 3-year-old with IFAP syndrome.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
JAK inhibitors show promise in treating moderate to severe alopecia areata.
9 citations
,
May 2013 in “JAMA Dermatology” A woman's hair turned white after taking a cancer drug called dasatinib.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Targeting specific metabolic and ionic pathways may improve alopecia areata treatment.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
April 2023 in “Journal of Investigative Dermatology” The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
May 2026 in “International Journal of Molecular Sciences” Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.